Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study
Table 1
Demographic and baseline characteristics of Chinese and Caucasian participants.
Characteristics
Tenapanor 10 mg (n = 12)
Tenapanor 30 mg (n = 12)
Tenapanor 50 mg Chinese (n = 12)
Tenapanor 50 mg caucasian (n = 11)
Placebo (n = 12)
Total (n = 59)
Age (years)
26.7 ± 6.46
26.7 ± 4.60
28.6 ± 5.21
28.8 ± 4.51
26.2 ± 4.37
27.4 ± 5.04
Male (n, (%))
9 (75.0)
9 (75.0)
7 (58.3)
7 (63.6)
7 (58.3)
39 (66.1)
Height (cm)
163.92 ± 5.783
167.25 ± 10.376
162.96 ± 10.290
171.36 ± 9.440
166.92 ± 9.695
166.40 ± 9.415
Weight (kg)
59.42 ± 10.562
63.74 ± 7.754
57.80 ± 7.924
65.66 ± 10.196
62.57 ± 11.403
61.77 ± 9.761
BMI (kg/m2)
22.027 ± 3.1629
22.802 ± 2.2143
21.742 ± 1.9196
22.312 ± 2.4982
22.315 ± 2.3189
22.238 ± 2.3980
Subjects with any history of disease (n, (%))
1 (8.3)
1 (8.3)
1 (8.3)
1 (9.1)
2 (16.7)
6 (10.2)
Note. Data are shown as mean ± SD, unless otherwise specified.
